Pulnovo reports two U.S. procedures in the PULSE-LHD trial. The estimated 750-participant IDE study uses a sham control; no ...
The ravulizumab ARTEMIS trial has been terminated at 555 patients. Read alone it is one failed study. Read against the registry it is the sixth attempt to take a rare-disease drug into a large ...
Put this method on a file you are actually deciding. Witfire Elite provides pharmaceutical due diligence services built on the method used in every brief published here: every figure traced to a ...
Johnson & Johnson won a causation ruling. One week later it settled anyway. Understanding why explains everything else about this deal. The J&J talc settlement announced on 27 July 2026 commits $5.5 ...
OX40 atopic dermatitis development ended this month. Sanofi said on 24 July it will not file amlitelimab, four months after Kyowa Kirin halted every rocatinlimab trial on safety grounds. Both ...
Witfire Elite · Clinical Catalysts · Registry Analysis The ravulizumab ARTEMIS trial has been terminated at 555 patients. Read alone it is one failed… ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results